SuperGen Submits Name Rubivive For Cancer Drug; Plans ‘02 Rubitecan NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SuperGen submits Rubivive as potential tradename for a cancer therapy, presumably rubitecan. The firm says it has selected a tradename for rubitecan that will be announced in the future. SuperGen plans to submit an NDA for the drug in 2002. Ilex may choose Eflorex as name for its oncology agent eflornithine, in Phase III study for superficial bladder cancer